Immunome Stock Forecast

Stock Price Forecast

According to 14 analysts polled by S&P Global, Immunome stock has a consensus rating of "Strong Buy" and an average price target of $35.77. The average 1-year stock price forecast is 56.89% higher than the current stock price, while the lowest is $30 (+31.58%) and the highest is $40 (+75.44%).

Price Target: $35.77 (+56.89%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$30	$35.77	$36	$40
Change	+31.58%	+56.89%	+57.89%	+75.44%

Analyst Ratings

The average analyst rating for Immunome stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '26	Mar '26	Apr '26	May '26	Jun '26	Jul '26
Strong Buy	12	12	12	12	11	11
Buy	2	2	2	3	3	3
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	14	14	14	15	14	14

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Lukas Shumway Barclays	Barclays	Buy Maintains $36	Buy	Maintains	$36	+57.89%	Jul 9, 2026
Andres Y. Maldonado H.C. Wainwright	H.C. Wainwright	Buy Reiterates $40	Buy	Reiterates	$40	+75.44%	Jul 9, 2026
Charles Zhu LifeSci Capital	LifeSci Capital	Buy Maintains $40	Buy	Maintains	$40	+75.44%	Jul 8, 2026
Brian Cheng J.P. Morgan	J.P. Morgan	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jun 30, 2026
Unknown Analyst Wedbush No rating	Wedbush	Buy Maintains $31	Buy	Maintains	$31	+35.96%	Jun 12, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

2.72M

from 6.94M

-60.86%

from 6.94M

Revenue Next Year

64.62M

from 2.72M

2,278.76%

from 2.72M

EPS This Year

-2.12

from -2.43

EPS Next Year

-2.12

from -2.12

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	14.02M	9.04M	6.94M	2.72M
Revenue Growth	-	-	-	-35.50%	-23.23%	-60.86%
Operating Income	-25.20M	-36.90M	-28.73M	-153.46M	-214.11M	-262.94M
Net Income	-24.71M	-36.90M	-106.81M	-292.96M	-212.39M	-248.61M
EPS	-	-	-	-	-2.43	-2.12
Free Cash Flow	-8.75M	-14.89M	-1.65M	-96.32M	-133.62M	-293.66M
No. Analysts	-	-	-	-	-	12

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	26.6M
Avg	2.7M
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	283.2%
Avg	-60.9%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-1.84
Avg	-2.12
Low	-2.45

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-